Zimmer Biomet Holdings Inc (NYSE:ZBH) shares are trading -0.42% thus far today and have traded in the range of 126.45 – 127.23 during the current session. In order to take a look at where the stock might headed longer term, we can also look at different sets of data. Sell-side research firms currently have a consensus one year price target of $140.85 on the stock according to First Call. This number can often vary from the Zacks or FactSet mean targets. The sell-side analysts are projecting earnings per share of $2.16 for the next fiscal quarter. For the current year, analysts are predicting earnings of $7.97 per share according to First Call.
Stock Technicals in Focus
In looking at where the stock is trading on a technical level, the stock is trading -1.07% away from its 50 day moving average of $127.99. Based on the most recent available data, the equity is -4.95% off of its 52-week high of $133.21 and +43.45% away from its 52-week low which is $88.27. In taking a look at the company’s valuation, the firm’s price to earnings ratio stands at 115.63. This is a crucial indicator investors watch as higher ratios compared to peers, would suggest higher future earnings growth potential for the stock. The price to current year EPS estimates from research analysts currently stands at 15.89. In looking further ahead, potential investors should note that the company’s price to next year’s EPS estimates is 14.34.
Today, the stock opened at $127.16 and the last bid at the time of writing stood at $126.62. During the session thus far, the equity dipped down to $126.45 and touched $127.23 as the high point. Zimmer Biomet Holdings, Inc. Co has a market cap of 25.33B and has seen an average daily volume of 1213320 over the past three months.
During the most recent trading session, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares traded -1.33%. Tracking the stock price in relation to moving averages may provide enhanced perspective on stock performance. After a recent look, the stock has been seen trading $-29.81 off of the 50-day moving average of $396.54 and $-25.79 separated from the 200-day moving average of $392.52. Taking a further look from a different perspective, the stock has been recently recorded -38.11% off of the 52-week high of 592.59 and +11.44% apart from the 52-week low of 329.09. Monitoring stock price activity relative to moving averages and the highs and lows for the past year might help with future stock price value assessment.
Price Target in Focus
While monitoring stock technicals is important, most investors are more concerned with where the stock might be going now. Equity research analysts have provided views on where they believe the stock will be trading in the future. According to Thomson Reuters, sell-side analysts are projecting a consensus target price of $467.73 on company shares. This is a near-term estimate for the next 12-18 months.
Currently, Regeneron Pharmaceuticals, Inc. has a price to earnings ratio of 57.21. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The stock currently has a PEG Ratio of 1.91.